Zevra Therapeutics (ZVRA) Total Debt Growth (3y) (2017 - 2025)
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Total Debt Growth (3y) (2017 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.08% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.52% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.76% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.30% |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 69.13% |
| Sep 30, 2025 | 68.57% |
| Jun 30, 2025 | 68.00% |
| Mar 31, 2024 | 264.88% |
| Dec 31, 2023 | 279.74% |
| Sep 30, 2023 | -16.52% |
| Jun 30, 2023 | -42.84% |
| Mar 31, 2023 | -42.69% |
| Dec 31, 2022 | 22.40% |
| Sep 30, 2022 | 23.97% |
| Jun 30, 2022 | 25.36% |
| Mar 31, 2021 | -38.35% |
| Dec 31, 2020 | -38.35% |
| Jun 30, 2019 | 49.82% |
| Mar 31, 2019 | 56.91% |
| Dec 31, 2018 | -38.78% |
| Sep 30, 2018 | -38.45% |
| Jun 30, 2018 | -33.49% |
| Mar 31, 2018 | -33.01% |
| Dec 31, 2017 | -34.13% |